NuclixBio

NuclixBio is a preclinical-stage biotechnology company focused on the early research and development of intracellular targeting nucleic acid therapies based on proprietary platform technology. NuclixBio owns its circular mRNA platform, ringRNA™, and has established additional robust therapeutic platforms such as Ribo-TaP™ and Ribo-grAb™, which are currently being developed to target oncology and immuno-oncology treatment assets.